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ARTICLE
A splice variant in the ACSL5 gene relates migraine
with fatty acid activation in mitochondria
Fuencisla Matesanz*,1,4, María Fedetz1,4, Cristina Barrionuevo1, Mohamad Karaky1, Antonio Catalá-Rabasa1,
Victor Potenciano1,2, Raquel Bello-Morales3, Jose-Antonio López-Guerrero3 and Antonio Alcina*,1,4
Genome-wide association studies (GWAS) in migraine are providing the molecular basis of this heterogeneous disease, but
the understanding of its aetiology is still incomplete. Although some biomarkers have currently been accepted for migraine, large
amount of studies for identifying new ones is needed. The migraine-associated variant rs12355831:A4G (P=2×10−6),
described in a GWAS of the International Headache Genetic Consortium, is localized in a non-coding sequence with unknown
function. We sought to identify the causal variant and the genetic mechanism involved in the migraine risk. To this end, we
integrated data of RNA sequences from the Genetic European Variation in Health and Disease (GEUVADIS) and genotypes
from 1000 GENOMES of 344 lymphoblastoid cell lines (LCLs), to determine the expression quantitative trait loci (eQTLs) in the
region. We found that the migraine-associated variant belongs to a linkage disequilibrium block associated with the expression of
an acyl-coenzyme A synthetase 5 (ACSL5) transcript lacking exon 20 (ACSL5-Δ20). We showed by exon-skipping assay a direct
causality of rs2256368-G in the exon 20 skipping of approximately 20 to 40% of ACSL5 RNA molecules. In conclusion, we
identiﬁed the functional variant (rs2256368:A4G) affecting ACSL5 exon 20 skipping, as a causal factor linked to the migraine-
associated rs12355831:A4G, suggesting that the activation of long-chain fatty acids by the spliced ACSL5-Δ20 molecules, a
mitochondrial located enzyme, is involved in migraine pathology.
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INTRODUCTION
Migraine is the most frequent type of headache in children. It also
affects approximately 14% of adult population, being more frequent
in women (20%) than in men (8%). It has a strong genetic basis with
heritability estimated of 40–57%.1 The aetiology of migraine is starting
to be understood as a result of basic-clinical investigations and
genome-wide association studies (GWAS) applied to common form of
migraine.2–5 These investigations aim at getting biomarkers and
clinical targets for different types of migraine.6–9
An example of a biomarker currently accepted for the common
migraine with aura subtype is the MTHFR C677T polymorphism, for
which genetic testing is currently available and a nutraceutical treat-
ment is known to alleviate symptoms.10 Other classic example includes
the neuropeptide calcitonin gene-related peptide (CGRP) involved
in migraine, which are signiﬁcantly associated with response to speciﬁc
treatments for acute migraine attacks and prophylaxis. CGRP can
stimulate the release of pro-inﬂammatory cytokines, some of which are
established to contribute to both the risk of and the outcome from
cerebrovascular disease.11
One of the largest migraine GWAS data set currently available3 from
the the International Headache Genetics Consortium performed on 29
populations, including a total of 23 285 individuals with migraine and
95 425 controls, identiﬁed 142 polymorphisms located in 12 different
loci, signiﬁcantly associated with the phenotype. Some of the loci point
to new genes (near AJAP1 on 1p36, near TSPAN2 on 1p13, within
FHL5 on 6q16, within c7orf10 on 7p14, and near MMP16 on 8q21)
and others conﬁrm previous reports. Three of these loci were identiﬁed
in disease subgroup analyses. Expression quantitative trait loci (eQTLs)
analysis performed on 394 brain tissue specimens revealed 5 additional
loci potentially implicated in migraine susceptibility (APOA1BP,
TBC1D7, FUT9, STAT6 and ATP5B). Some additional loci
showed suggestive evidence for association in the combined data
(Po1 ´ 10− 6), but failed to surpass the genome-wide signiﬁcance
threshold. Different functional studies3,8,9 suggest the involvement of
pathways for glutamatergic neurotransmission, synaptic function, pain
sensing, metalloproteinases, and the vasculature, key elements in the
anatomical alterations seen in the migraine brain.
The complexity of migraine pathology with features that may have
different genetic causes12,13 complicates the discovery of genuinely-
associated genes. In addition, one important reason to fail in assigning
causal genes of complex diseases by GWAS is the fact that
the associated signals used to be found in non-coding sequences,
often containing multiple genes, and the proximity criteria to the top
hits, used for selecting putative disease-responsible genes, are not
always correct. Some of these genes may actually represent the genetic
alteration responsible for the disease association, but for most of them,
they merely tag a block of several variants in linkage disequilibrium
(LD) in a nearby gene.14,15
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Furthermore, current GWAS top hits of complex conditions explain
only a small part of the disease heritability; and therefore, genes identiﬁed
in this way reﬂect only a fraction of the pathways conferring genetic
disease risk. Rare or family-speciﬁc variants have been missed using
GWAS approach and could explain the lack of hits to date. As many
variants with small effect size are likely to confer disease risk, very large
sample sizes, perhaps even hundreds of thousands of individuals are
needed to provide sufﬁcient statistical power.15,16 Finally, positive signals
with subGWAS level of signiﬁcance (P-values45×10−8) constitute
another subgroup of variants that may represent truely-associated loci
and it is worth to restudy in larger sample sizes or disease subtypes.17
In this study, we analysed the migraine-associated variant
rs12355831:A4G, localized at chr10:g.114202526 (hg19), reported
in a migraine GWAS performed by the International Headache
Genetic Consortium.3 This migraine-associated variant was located
in an intronic region of ZDHHC6 gene, with unknown function, and it
was studied considering an expression regulatory role. We found a
functional variant (rs2256368:A4G) in the LD block tagged by the
migraine-associated polymorphism, in the intron 20 of ACSL5 gene
(NM_016234.3), and showed it was responsible for the ACSL5 exon 20
skipping. This exon 20 spliced ACSL5 RNA isoform may produce a
protein that lacks the peptide corresponding to the sequence of exon
20 (splice variant ACSL5-Δ20). We discuss a hypothetical pathogenic
mechanism involving the possible dysfunctional enzymatic activity of
the splice variant ACSL5-Δ20 in the frame of the evidence, indicating a
disarrangement of the mitochondrial energy metabolism and apoptosis
mechanisms in migraine.
MATERIALS AND METHODS
Gene expression and genotype integration analysis
For this study, we used the data from RNA-Seq from European lymphoblastoid
cell lines (LCLs) of the GEUVADIS RNA sequencing Project (ftp://ftp.ebi.ac.uk/
pub/databases/microarray/data/experiment/GEUV/E-GEUV-1/analysis_results/).18
For the eQTLs determination, we used the genotypes of the same
LCLs, obtained from the 1000 Genomes Project19 (phase 1 release v.3)
(http://www.1000genomes.org/) as previously reported.20 For Gene Expression
Proﬁling analysis, reads were mapped to the human reference genome
(assembly GRCh37.68) as reported.20
Nomenclature and database submission
The nomenclature system for the description of the DNA variant rs2256368:
A4G and the corresponding changes in RNA and protein follows the
recommendations of the Human Genome Variation Society, with numbering
starting at the ﬁrst position of the translation initiation codon of the GenBank
RefSeq NM_016234.3. Thus, rs2256368:A4G was located in chr10:g.114186624:
A4G (hg19), in the intron 20 of ACSL5 gene (ACSL5 c.2079+7G4A), whose G
allele affects exon 20 skipping (ACSL5 c.2007_2079del), potentially translated into
a protein sequence with exon 20 deleted (p.Val671_Val694del). This variant
information has been submitted to the LOVD 3.0/shared (http://databases.lovd.nl/
shared/view/ACSL5) with the submission ID #60251.
Reverse transcriptase and quantiﬁcation by qPCR
Total RNA from different LCLs carrying the three rs2256368:A4G genotypes
(CODE, AA genotype: GM12006E, GM11994E, GM12043, GM11993D; AG:
GM12004D, GM12044E, GM12144D, GM12717L; GG: HG00134, HG00326,
HG01048, HG01383) was extracted and processed as previously reported.20
ACSL5 RNA quantiﬁcations by relative qPCR were normalized to UBE2D2
mRNA levels, using 2E ΔCt (ΔCt=Ct sample−Ct reference) method
as described.21 The primer sequences were designed using Primer3 browser
(key: forward-Fw; reverse-Rv; E, exon; 5'-3' direction): UBE2D2 Fw-CAATTCCG
AAGAGAATCCACAAGGAATTG and Rv-GTGTTCCAACAGGACCTGCTGAA
CAC; non-Spliced E20 (using bridge E19–E20 to E21) Fw-CCAAGTTGTAAGGG
AAGCCA and Rv-GCTGTCAATTTGGGTCCGAA; Spliced E20 (using bridge
E19–E21 to E21) Fw-ACTGTGCCAAAACCAAGTCA and Rv-TGTGCTCATAC
AGGCTGTCA; and Non-Spl (E19–E21) Fw-CTTCCCTCATTTGCAGCCAA
and Rv-GCTCTCCTCGCTTTGCTTTC. Thermocycling conditions for all these
ampliﬁcations were 1× (95 °C, 3 min); 30× (95 °C for 20 s, 59 °C for 20 s, 72 °C
for 20 s).
Exon splicing assay
Alternative E20 splicing analysis was performed as previously described.20,22
Brieﬂy, we carried out a PCR ampliﬁcation of a genomic DNA fragment
(698 bp) containing the E20 of ACSL5 gene (73 bp) and ﬂanking intronic
sequences (335 bp at the 5′ and 290 bp at the 3′ of the exon 20) from the LCL
GM12004D (rs2256368-AG) using the following oligonucleotides: Fw- 5′-GCA
GCCCAAACAGACTGAA and Rv- 5′-TGCTCTGTGAAGAAAGTGAGG. This
was performed by Expand High Fidelity PCR System (Roche Diagnostics
GmbH, Mannheim, Germany) under the following PCR thermocycling
conditions: 1 × (94 °C for 2 min); 30 × (94 °C for 15 s, 59 °C for 30 s, 72 °C
for 45 s); 1 × (72 °C for 7 min). The PCR products were puriﬁed from 2%
agarose-gel electrophoresis with QiaexII gel extraction kit (QIAGEN GmbH,
Hilden, Germany), cloned in pCR-2.1 vector (TOPO-TA Cloning Kit,
Invitrogen, Carlsbad, CA, USA) and sequenced to identify the clones carrying
each allele and to discard potential PCR errors. An EcoRI fragment from each
TOPO vector was again puriﬁed from agarose-gel electrophoresis and
subcloned into the EcoRI site of the pSPL3 minigene plasmid, which was
previously cut with EcoRI and puriﬁed from agarose gel using QiaexII gel
extraction kit (QIAGEN GmbH), and dephosphorylated using FastAP Thermo-
sensitive Alkaline Phosphatase (ThermoFisher Scientiﬁc Inc, Leicestershire,
UK). Colonies were checked by sequencing for pSPL3 plasmids containing
inserts in the right orientation with respect to the promoter of the vector. The
pSPL3 plasmids bearing ‘A’ and ‘G’ allele fragments (pA, pG) and plasmid
without insert (p) were transfected in HEK cells using JetPrime Transfection
reagent (Polyplus Transfection SA, Illkirch-Graffenstaden, France) and har-
vested 24 h after transfection. After RNA extraction, the cDNA was produced
using oligo-dT with SuperScript III First Strand Synthesis Super Mix (Invitro-
gen) and ampliﬁed by PCR using vector-speciﬁc primers SD6 (5′-
TCT GAG TCA CCT GGA CAA CC-3′) and SA2 (5′-
ATC TCA GTG GTA TTT GTG AGC-3′) under the following thermocycling
conditions: 1 × (95 °C for 2 min); 30× (95 °C for 20 s, 58 °C for 30 s and 72 °
C for 1 min); 1 × (72 °C for 7 min). The PCR products were sequenced and
visualized in 2% agarose-gel electrophoresis.
Statistical calculations
We conducted Spearman's rank correlation analyses with single-nucleotide
polymorphisms (SNPs) from the 1000 Genomes Project phase 1 release v3 data
set with MAF (minor-frequent allele)40.05 and the transcript expression levels
from GEUVADIS. The setting of an MAF of ⩾0.05, excluding all rare variants to
detect eQTLs, was necessary as the transcriptomes used to determine the eQTLs
were from 344 subjects (LCLs from 1000 Genomes). MAF o0.05 would have
not power enough to obtain eQTLs of rare variants. A P-value of false discovery
rate was obtained as previously indicated.10 Quantiﬁcation by qPCR experiments
was performed in triplicates and two to four independent experiments.
RESULTS
Different GWAS variants in the analysed region
The genomic region analysed in this study (Figure 1) has been
associated with different diseases by GWAS, as it is indicated in the
UCSC Genome Browser, such as blood lipid levels (rs2255141);
migraine (rs12355831); colorectal cancer (rs12241008); and multiple
sclerosis brain lesion distribution (rs17267338). As all of these SNPs
were located either in intronic or in intergenic non-coding sequences,
we designed this study considering their expression regulatory role.
Linkage disequilibrium in the region and eQTLs
We ﬁrst searched for SNPs associated with gene expression (eQTLs)
by means of processing the RNA-sequencing reads from GEUVADIS
Project18 and the genotypes of the same 344 LCLs from 1000 Genomes
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Project.19 This integration of data sets resulted in the ﬁnding of a high
LD block (r240.8) (Figure 2) of a set of variants, including the
migraine-GWAS rs12355831:A4G, but not the other GWAS SNPs in
the region, associated with changes in the expression of two ACSL5
transcripts (ENST00000433418, ENST00000356116) from Ensembl
that showed alternative splicing of the exon 20 (E20).
Expression association
Among the variants in the LD block, we selected rs2256368:A4G as
the best eQTL in total LD (r2= 1) with the migraine-associated
variant, located at 7 bases downstream of the splicing acceptor site of
E20. This position has been described as essential for the interaction
with the U1 snRNP component of the spliceosome;23 and therefore, it
was considered as a potential candidate that could affect the splicing
of the E20.
ACSL5 RNA isoforms quantiﬁcation was performed as previously
described,20 indicated in the ﬁgure as FPKM (fragments per kilobase
of exon per million fragments mapped), with and without E20, in 344
LCLs versus the rs2256368:A4G genotypes (Figure 3), showing
opposite correlations with the genotypes of the best ACSL5 eQTL
variant. Thus, the colocalization by LD of the migraine-GWAS variant
and the best ACSL5 QTL implied that both signals point to the same
causality.
Quantiﬁcation of ACSL5 RNA isoforms
To quantify the expression levels of the two ACSL5 RNA isoforms
and to validate the data obtained by integrating the RNA-Seq from
GEUVADIS and genotypes from 1000 Genomes, we performed real-
time RTqPCR with RNA from 12 LCLs of known genotypes for the
variant rs2256368:A4G (Figure 4). Genotype GG was infrequent in
503 subjects from EUR population (F= 0.002), getting only four LCLs
with rs2256368-GG genotypes in the whole LCL collection. These
results were also visualized in polyacrylamide gel electrophoresis after
performing end-point classic PCR, using bridge primers for E19–E20
(non-spliced E20) and E21–E19 (spliced E20). As observed in Figure 4,
ACSL5 transcripts lacking E20 were expressed about 16- to 31-fold
higher in cells bearing GG than AA genotypes, as resulted from qPCR
value comparisons of GG versus AA genotypes in Figure 4b. Cells
bearing GG genotypes expressed 27–43% of spliced E20 with respect
to non-spliced E20 isoforms as calculated from the qPCR values of GG
in Figure 4b versus GG in Figure 4a.
Direct causality of rs2256368:A4G variant in E20 skipping
To conﬁrm that the rs2256368:A4G is the causal variant of the E20
splicing observed in the ACSL5 transcript proﬁle, we used a strategy by
cloning the E20 and its ﬂanking intronic sequences, carrying as unique
difference the two rs2256368:A4G alleles, into the pSPL3 plasmid
Figure 1 Genomic region in the chromosome 10 associated with different diseases. As obtained from UCSC Genome Browser, the scheme shows from top to
bottom: the scale and position, the set of variants (blue) associated with the expression of the ACSL5 transcripts (red), in high LD with the migraine-
associated rs12355831:A4G SNP (green), and the Ref-Genes in the region (dark blue).
Figure 2 Linkage disequilibrium (LD) of the GWAS variants with the best eQTL. LocusZoom plots showing the LD (colour scales) of the GWAS/disease-
associated variants, with the best eQTL-associated SNP in the ACSL5 locus, rs2256368:A4G, obtained from 1000 Genomes EUR population (arrows). Only
the migraine-associated GWAS variant was in total LD (r2=1) with the rs2256368:A4G SNP. Colour scales represent the LD intervals (r2 values).
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(Figure 5). After transfection in HEK cells, RNA puriﬁcation, RT-PCR
ampliﬁcation, analysis of the RNA products by agarose-gel electro-
phoresis and sequencing, we determined that the E20-G allele was
spliced in about 40% of the molecules and o5% of the molecules in
the E20-A allele. These splicing percentages varied in different
experiments in which the length of the ﬂanking intronic sequences
of E20 was changed (not shown). Therefore, these data were in
agreement with the previous results of this study, conﬁrming that the
rs2256368-G allele was associated with splicing alterations resulted in
the expression of ACSL5 RNA isoforms lacking E20 (ACSL5-Δ20).
DISCUSSION
In this work, we have shown the SNP rs2256368:A4G, in total LD
(r2= 1) with migraine GWAS-associated rs12355831:A4G3, as the
causal genetic determinant responsible for the expression of ACSL5
transcript variant lacking E20 (ACSL5-Δ20). Although activity of
eQTLs can be cell type and stimulus dependent,20,21 the ACSL5
enzyme (EC 6.2.1.3) is expressed in all tissues and cells at different
levels, some times under speciﬁc cell stimulation.21,24 So it is very
likely that the studied eQTL is also operating in brain tissue, where
migraine disorder takes place.
This enzyme is localized in the mitochondrial outer membrane and
microsomes25 where it catalyses the activation of long-chain fatty acids
by thioesteriﬁcation with coenzyme A (CoA). ACSL5 is thus having an
important role in supplying exogenous fatty acids into the mitochon-
dria (mt) for oxidative reactions, increasing ceramide synthesis,
acylation of proteins, and affecting the mitochondrial membrane
potential.26–28 Furthermore, ACSL5 has been involved in the regulation
of cell growth, pro-apoptotic sensing of enterocytes,26 and mitogen-
activated lymphocytes.24 Human ACSL5 is shown to be experimentally
inhibited by triacsin C29 and may be the target of drug actions as
shown in different experimental systems.29–31
Given the limited knowledge on the functional activity of the
ACSL5Δ20 enzyme, it is difﬁcult to envisage the pathogenic relevance
in migraine of the risk rs2256368-GG carriers, ‘high producers’
of ACSL5-Δ20. As described by Gassler et al.,26 in contrast with the
splice variant ACSL5-Δ20, recombinant and puriﬁed full-length
enzyme is active at high alkaline pH. Therefore, the genetic factor
associated with pathogenesis of the migraine may be related with some
type of dysfunction of the protein lacking E20 peptide. On the other
hand, the fact that ACSL5 is the only member of the ACSL family
(including ACSL1, 3, 4, 5 and 6) located in the mt, indicates that the
enzymatic activity affected in the splice variant ACSL5Δ20 is relevant
to migraine pathology only in this suborganelle.
The hypothesis of the mitochondrial component in migraine
neurobiology has been supported in several studies,32–37 suggesting
that an impairment of the mitochondrial oxidative metabolism,
which ultimately causes energy failure in neurons and astrocytes,
triggers migraine mechanisms. Furthermore, different types of assays
performed in migraine sufferers have shown a decreased activity of the
respiratory chain enzymes33 and a correlation between the extent of
the energy disturbance (low ATP levels), and the clinical phenotype
severity.37 Our data suggest that the acyl-CoAs produced by ACSL5
enzyme or the downstream metabolism of these activated fatty acids
(for beta-oxidation, mitochondrial membrane integrity, and protein
acylation) could be altered by the presence of the splice variant
ACSL5Δ20, as carriers of the rs2256368-GG genotype produced about
40% of ACSL5 molecules lacking E20.
Several compounds such as riboﬂavin/vitamin B2, CoQ10, magne-
sium, niacin, carnitine, topiramate, and thioctic acid/lipoic acid, that
have a positive effect on mitochondrial metabolism, have been shown
to prevent recurrent headaches.34,35 This evidence is in agreement with
the hypothesis of dysfunctional energy metabolism, in which ACSL5
is implicated by supplying activated fatty acids for beta-oxidation or
acylation of other mitochondrial proteins and ceramides. Speciﬁc
mitochondrial DNA mutations have not been detected in patients with
migraine;33 thus, this ACSL5 rs2256368:A4G would be an SNP of
a nuclear gene encoding for a mitochondrial protein.
Figure 3 Correlation of the rs2256368:A4G genotypes with the expression
levels of two ACSL5 RNA isoforms in 344 LCLs, represented in box plots.
Data were obtained by integration of the GEUVADIS RNA-sequencing
data and 1000 Genomes genotypes of the same LCLs. Statistical analysis
was performed by Spearman's correlation test. Correlation index (rho) and
P-values (p) are indicated inside the plots.
Figure 4 Quantiﬁcation of the ACSL5 RNA isoforms from different LCLs
carrying the three rs2256368:A4G genotypes. Classic PCR ampliﬁcation
visualized by acrylamide-gel electrophoresis and relative real-time qPCR
values, reﬂecting the ratio between the expression levels of the ACSL5
transcripts versus the levels of the reference gene, are indicated in the
following panels: (a) ACSL5 transcript levels containing E20 (non-spliced
E20) by ampliﬁcation with a bridge primer in E19–E20 to E21; (b) ACSL5
transcript levels lacking E20 (spliced E20) by ampliﬁcation with a bridge
primer in E19–E21 to E21; (c) ACSL5 transcripts with and without E20 by
ampliﬁcation with primers E19–E21.
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Another hypothesis of how the splice variant ACSL5-Δ20 could be
involved in a mitochondrial dysfunction might be suggested from the
acyl-CoA synthetase-1 study in the malaria parasite Plasmodium
falciparum (PfACS1).38 This protein physically interacts through its
carboxyl-terminal domain with the erythrocyte ankyrin, as part of its
role in capturing serum fatty acids for activation and posterior
utilization by the intracellular parasites. This ankyrin-interacting domain
in PfACS1 is likely the equivalent region of the human ACSL5-E20. It is
tempting to speculate that the lack of E20 could affect the process of
protein–protein interactions of ACSL5 with other enzymes involved in
the processing of the acyl-CoAs in the mt and/or microsomes. As a
matter of fact, ACSL5 mediates antiproliferative activities via Wnt2B
palmitoylation in the mt with diminished Wnt activity.39
In support of the hypothesis, ACSL5 interacts with ceramide
synthases (CerS) and diacylglycerol acyltransferase 2 (DGAT2) to
form a ACSL5–CerS–DGAT2 complex,40 in which ACSL5 provides
activated long-chain fatty acids, CerS generates de novo synthesis of
ceramides and the DGAT2 catalyses the transference of the fatty acids
to ceramides, to ﬁnally produce acyl-ceramides. If channelling of novo
ceramides to acyl-ceramides is inhibited, then an increase in ceramide-
mediated apoptosis is produced.41 Spliced ACSL5-Δ20 could be
unable to form the tri-molecular complex, and as a result, decreasing
the acyl-ceramides produced. A recent biomarker study42 has shown
that ceramides were decreased in the blood of women with episodic
migraine as compared with those women without any headache
disorders. If conﬁrmed, the link between the SNP rs2256368:A4G
and a low production of acyl-ceramides may take place as a
consequence of a dysfunctional spliced ACSL5-Δ20, supporting its
implication in migraine pathology.
Gene-based analysis of the migraine GWAS data, using detailed
spatial gene expression data in the normal human brain,43 have shown
moderate enrichment of migraine-associated genes in modules
involved in cortical neurotransmission, mitochondrial and oligoden-
drocyte function that provide further evidence that these mechanisms
have a causal role in migraine, and again supporting the molecular
activity reported for ACSL5 enzyme in apoptosis and cell
differentiation.
In summary, this study contributes to the identiﬁcation of a
functional SNP (rs2256368:A4G) in total LD with the migraine
GWAS-associated variant (rs12355831:A4G). Carriers of rs2256368-
GG produce a measurable molecular phenotype affected by E20
skipping in the transcripts of ACSL5 gene. Hypothetically, a spliced
ACSL5-Δ20 enzyme, lacking amino-acid sequence of E20
(p.Val671_Val694del), could be unable of interacting with CerS and
DAGT2 complex to form acyl-ceramides. These lipids are involved in
early apoptosis induced from mt and are decreased in blood of women
with sporadic migraine. This mechanism is congruent with the activity
that ACSL5 performs in the energy metabolism, synthesis of acyl-
ceramides and mitochondrial apoptosis, suggesting that the spliced
ACSL5-Δ20 is implicated in the pathogenesis of migraine.
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